Literature DB >> 10224051

Nuclear IkappaBbeta maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells.

C DeLuca1, L Petropoulos, D Zmeureanu, J Hiscott.   

Abstract

Monocytic cells exhibit constitutive NF-kappaB activation upon infection with human immunodeficiency virus-1 (HIV-1). Because IkappaBbeta has been implicated in maintaining NF-kappaB.DNA binding, we sought to investigate whether IkappaBbeta was involved in maintaining persistent NF-kappaB activation in HIV-1-infected monocytic cell lines. IkappaBbeta was present in the nucleus of HIV-1-infected cells and participated in the ternary complex formation with NF-kappaB and DNA. In contrast to uninfected cells, the addition of recombinant glutathione S-transferase-IkappaBalpha protein to preformed NF-kappaB.DNA complexes from HIV-1-infected cell extracts did not completely dissociate the complexes, suggesting that IkappaBbeta may protect NF-kappaB complexes from IkappaBalpha-mediated dissociation. Immunodepletion of IkappaBbeta resulted in an NF-kappaB.DNA binding complex that was sensitive to IkappaBalpha-mediated dissociation, thus demonstrating the protective role of IkappaBbeta. In addition, co-transfection studies with an NF-kappaB-dependent reporter construct demonstrated that IkappaBbeta co-expression partially alleviated inhibition of NF-kappaB-mediated gene expression by IkappaBalpha, implying that IkappaBbeta can maintain transcriptionally active NF-kappaB.DNA complexes. Furthermore, constitutive phosphorylation of IkappaBalpha was observed. Immunoprecipitation of the IkappaB kinase (IKK) complex followed by in vitro analysis of kinase activity demonstrated that IKK was constitutively activated in HIV-1-infected myeloid cells. Thus, virus-induced constitutive IKK activation, coupled with the maintenance of a ternary NF-kappaB.DNA complex by IkappaBbeta, maintains persistent NF-kappaB activity in HIV-1-infected myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224051     DOI: 10.1074/jbc.274.19.13010

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

Review 3.  Hostile takeovers: viral appropriation of the NF-kappaB pathway.

Authors:  J Hiscott; H Kwon; P Génin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 4.  Ubiquitination and auxin signaling: a degrading story.

Authors:  Stefan Kepinski; Ottoline Leyser
Journal:  Plant Cell       Date:  2002       Impact factor: 11.277

Review 5.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

6.  Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras.

Authors:  Yi Chen; Sebastien Vallee; Joann Wu; Don Vu; John Sondek; Gourisankar Ghosh
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Analysis of SRrp86-regulated alternative splicing: control of c-Jun and IκBβ activity.

Authors:  Amanda S Solis; James G Patton
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 8.  Viral subversion mechanisms in chronic kidney disease pathogenesis.

Authors:  Leslie A Bruggeman
Journal:  Clin J Am Soc Nephrol       Date:  2007-07       Impact factor: 8.237

Review 9.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

10.  IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo.

Authors:  Melanie Scheibel; Bettina Klein; Heidrun Merkle; Manon Schulz; Ralph Fritsch; Florian R Greten; Melek C Arkan; Günter Schneider; Roland M Schmid
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.